NCT05815901View on ClinicalTrials.gov

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

588

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Gout
Interventions
DRUG

Epaminurad 6 mg

Epaminurad 6 mg tablet

DRUG

Epaminurad 9 mg

Epaminurad 9 mg tablet

DRUG

Febuxostat 40 mg

Febuxostat 40 mg tablet

DRUG

Febuxostat 80 mg

Febuxostat 80 mg tablet

DRUG

Epaminurad 6 mg placebo

Placebo tablet

DRUG

Epaminurad 9 mg placebo

Placebo tablet

DRUG

Febuxostat 40 mg placebo

Placebo tablet

DRUG

Febuxostat 80 mg placebo

Placebo tablet

Trial Locations (1)

Unknown

RECRUITING

Inha University Hospital, Incheon

Sponsors

Lead Sponsor

JW Pharmaceutical
All Listed Sponsors
lead

JW Pharmaceutical

INDUSTRY

NCT05815901 - A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients | Biotech Hunter | Biotech Hunter